131 related articles for article (PubMed ID: 25841397)
1. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.
Zhan P; Wang Q; Qian Q; Yu LK
Chin Clin Oncol; 2012 Dec; 1(2):19. PubMed ID: 25841397
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.
Gao S; Ma JJ; Lu C
Tumour Biol; 2014 Jan; 35(1):603-13. PubMed ID: 23959477
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
Bennett CL; Silver SM; Djulbegovic B; Samaras AT; Blau CA; Gleason KJ; Barnato SE; Elverman KM; Courtney DM; McKoy JM; Edwards BJ; Tigue CC; Raisch DW; Yarnold PR; Dorr DA; Kuzel TM; Tallman MS; Trifilio SM; West DP; Lai SY; Henke M
JAMA; 2008 Feb; 299(8):914-24. PubMed ID: 18314434
[TBL] [Abstract][Full Text] [Related]
4. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Cardiovascular Adverse Effects of Erythropoiesis Stimulating Agents in the Treatment of Cancer-Related Anemia: A Systematic Review of Randomized Controlled Trials.
Gergal Gopalkrishna Rao SR; Bugazia S; Dhandapani TPM; Tara A; Garg I; Patel JN; Yeon J; Memon MS; Muralidharan A; Khan S
Cureus; 2021 Sep; 13(9):e17835. PubMed ID: 34527499
[TBL] [Abstract][Full Text] [Related]
6. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
Sher A; Wu S
Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
[TBL] [Abstract][Full Text] [Related]
8. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
Rizzo JD; Brouwers M; Hurley P; Seidenfeld J; Arcasoy MO; Spivak JL; Bennett CL; Bohlius J; Evanchuk D; Goode MJ; Jakubowski AA; Regan DH; Somerfield MR; ;
J Clin Oncol; 2010 Nov; 28(33):4996-5010. PubMed ID: 20975064
[TBL] [Abstract][Full Text] [Related]
9. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
10. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
[TBL] [Abstract][Full Text] [Related]
12. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
13. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.
Kang J; Park J; Lee JM; Park JJ; Choi DJ
Int J Cardiol; 2016 Sep; 218():12-22. PubMed ID: 27209352
[TBL] [Abstract][Full Text] [Related]
14. VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia.
Dronca RS; Steensma DP
Nat Clin Pract Oncol; 2008 Sep; 5(9):504-5. PubMed ID: 18648351
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agents for anemic patients with cancer.
Sheikh S; Littlewood TJ
Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of chemotherapy-induced anemia].
Kadokura G; Katsumata N
Gan To Kagaku Ryoho; 2014 Apr; 41(4):416-20. PubMed ID: 24743356
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin in cancer-related anemia.
Fenner MH; Ganser A
Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
[TBL] [Abstract][Full Text] [Related]
18. Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.
Li X; Yan Z; Kong D; Zou W; Wang J; Sun D; Jiang Y; Zheng C
Chin J Cancer Res; 2014 Jun; 26(3):268-76. PubMed ID: 25035653
[TBL] [Abstract][Full Text] [Related]
19. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
Bohlius J; Tonia T; Schwarzer G
Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188
[TBL] [Abstract][Full Text] [Related]
20. Current status of use of erythropoietic agents in cancer patients.
Glaspy J
Semin Thromb Hemost; 2014 Apr; 40(3):306-12. PubMed ID: 24676903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
